Key statistics
On Friday, Neurocrine Biosciences Inc (NB3:STU) closed at 116.30, 17.69% above the 52 week low of 98.82 set on Nov 16, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 114.15 |
---|---|
High | 116.30 |
Low | 114.15 |
Bid | 116.55 |
Offer | 118.05 |
Previous close | 114.35 |
Average volume | 17.80 |
---|---|
Shares outstanding | 101.25m |
Free float | 99.60m |
P/E (TTM) | 33.67 |
Market cap | 12.73bn USD |
EPS (TTM) | 3.73 USD |
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Press releases
- Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules
- Neurocrine Biosciences to Participate at Investor Conferences in November
- Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules
- Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia
- Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
- Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results
- Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
- Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
- Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
- Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
More ▼